A small cog in a big wheel: PIK3CA mutations in colorectal cancer

Journal of the National Cancer Institute

Volumn 105, Issue 23, 2013, Pages 1775-1776

  Stintzing, Sebastian ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CETUXIMAB; CYCLOOXYGENASE 2; FLUOROURACIL; FOLINIC ACID; GROWTH FACTOR RECEPTOR; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE; PROTEIN TYROSINE KINASE;

BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL GROWTH; CODON; COLORECTAL CANCER; ENZYME ACTIVE SITE; EXON; LIVER; LIVER CANCER; LUNG CANCER; MUTANT; MUTATION; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RISK; STOMACH CANCER; SYNTHESIS; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84890480939     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt330     Document Type: Review

References (19)

1. Yang ZY, Wu XY, Huang YF, et al. Promising biomarkers for predicting the outcomes of patients with KRAS wild-Type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-Analysis. Int J Cancer. 2013;133(8): 1914-1925.
2. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.
3. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3) K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer. 2008;122(10):2255-2259.
4. Rosty C, Young JP, Walsh MD, et al., PIK3CA activating mutation in colorectal carcinoma: Associations with molecular features and survival. PLoS One. 2013;8(6):e65479.
5. Neumann J, Wehweck L, Maatz S, et al. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Arch. 2013;463(4):509-523.
6. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012;18(8):2257-2268.
7. Majek O, Gondos A, Jansen L, et al. Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. PLoS One. 2013;8(7):e68077.
8. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17): 1596-1606.
9. Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer [published online ahead of print September 23, 2013]. J Clin Oncol. PMID:24062397.
10. Viudez A, Hernandez I, Vera R. Aspirin, PIK3CA mutation, and colorectalcancer survival. N Engl J Med. 2013;368(3):289.
11. Smakman N, Kranenburg O, Vogten JM, et al. Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. Clin Cancer Res. 2005;11(1):41-48.
12. Sood A, McClain D, Maitra R, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-Type metastatic colorectal cancer. Clin Colorectal Cancer. 2012;11(2):143-150.
13. Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary N, Ng K, et al. Predictive and prognostic analysis of PIK3CA mutation in Stage III Colon Cancer Intergroup. J Natl Cancer Inst. 2013;105(23):1789-1798.
14. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456-3461.
15. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009;15(23):7322-7329.
16. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18(3):890-900.
17. Warren RS, Atreya CE, Niedzwiecki D, et al. Association of TP53 mutational status and gender with survival after adjuvant treatment for Stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013;19(20):5777- 5787.
18. Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer -A study of CALGB 9581 and 89803. J Clin Oncol. 2011;29(23):3153-3162.
19. Xie T, D' Ario G, Lamb JR, Martin E, Wang K, Tejpar S, et al. A comprehensice characterizatoin of genome-wide copy number abberation in colorectal cancer reveals novel oncogenes and patterns of alterations. PLoS one 2012;7(7):e42001.